Bezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapy

Página do item simplificado
dc.contributor.authorGeraix, Juliana [UNESP]
dc.contributor.authorde Souza, Micheli Evangelista [UNESP]
dc.contributor.authorDelatim, Francieli Cristina [UNESP]
dc.contributor.authorPereira, Paulo Câmara Marques [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:21:52Z
dc.date.available2014-05-27T11:21:52Z
dc.date.issued2006-06-01
dc.description.abstractThe use of highly active antiretroviral therapy (HAART) in HIV-infected patients has been associated with the development of risk factors for cardiovascular diseases (CD) including dyslipidemia and insulin resistance, hypertriglyceridemia being the most frequent metabolic disturbance in these patients. Fibrates are indicated when hypertriglyceridemia is accentuated and persists for over six months. We evaluated the efficacy and safety of bezafibrate for the treatment of hypertriglyceridemia in HIV-infected individuals on HAART. All patients received 400mg/day of bezafibrate and were evaluated three times: Mo (pre-treatment), M1 (one month after treatment), and M2 (six months after treatment). Fifteen adult individuals, eight males and seven females with mean age = 41.2 ± 7.97 years and triglyceride serum levels ≥400mg/dL were included in the study. Smoking, alcohol ingestion and sedentarism rates were 50%, 6.66% and 60%, respectively. Family history of CD, hypertension and diabetes mellitus was reported in 33.3%, 40% and 46.7% of the cases, respectively, while dyslipidemia was reported by only 13.3%. More than half of the patients were using a protease inhibitor plus a nucleotide analog transcriptase inhibitor. Eutrophy and tendency toward overweight were observed at all three study time points. There were significant reductions in triglyceride serum levels from Mo to M1 and from Mo to M2. No significant changes were observed in the serum levels of creatine phosphokinase, hepatic enzymes, CD4 +, CD8 + and viral load. Therefore, bezafibrate seems to be safe and effective for the reduction of hypertriglyceridemia in HIV-infected patients on HAART. © 2006 by The Brazilian Journal of Infectious Diseases and Contexto Publishing. All rights reserved.en
dc.description.affiliationTropical Diseases Department Faculty of Medicine of Botucatu State University of São Paulo - UNESP, Distrito de Rubiao Junior s/no, 18618-000 Botucatu, SP
dc.description.affiliationUnespTropical Diseases Department Faculty of Medicine of Botucatu State University of São Paulo - UNESP, Distrito de Rubiao Junior s/no, 18618-000 Botucatu, SP
dc.format.extent159-164
dc.identifierhttp://dx.doi.org/10.1590/S1413-86702006000300001
dc.identifier.citationBrazilian Journal of Infectious Diseases, v. 10, n. 3, p. 159-164, 2006.
dc.identifier.doi10.1590/S1413-86702006000300001
dc.identifier.file2-s2.0-33749079204.pdf
dc.identifier.issn1413-8670
dc.identifier.lattes1365320427418204
dc.identifier.orcid0000-0001-5771-8943
dc.identifier.scieloS1413-86702006000300001
dc.identifier.scopus2-s2.0-33749079204
dc.identifier.urihttp://hdl.handle.net/11449/68900
dc.language.isoeng
dc.relation.ispartofBrazilian Journal of Infectious Diseases
dc.relation.ispartofjcr2.083
dc.relation.ispartofsjr0,817
dc.rights.accessRightsAcesso aberto
dc.sourceScopus
dc.subjectBezafibrate
dc.subjectHAART
dc.subjectHIV
dc.subjectHypertriglyceridemia
dc.subjectantiretrovirus agent
dc.subjectbezafibrate
dc.subjectCD4 antigen
dc.subjectCD8 antigen
dc.subjectcedura retard
dc.subjectcreatine kinase
dc.subjectliver enzyme
dc.subjectproteinase inhibitor
dc.subjectRNA directed DNA polymerase inhibitor
dc.subjecttriacylglycerol
dc.subjectadult
dc.subjectalcohol consumption
dc.subjectcardiovascular disease
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectcreatine kinase blood level
dc.subjectdiabetes mellitus
dc.subjectdrug dose regimen
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectdyslipidemia
dc.subjectfamily history
dc.subjectfemale
dc.subjectfollow up
dc.subjecthighly active antiretroviral therapy
dc.subjecthuman
dc.subjectHuman immunodeficiency virus 1
dc.subjectHuman immunodeficiency virus infected patient
dc.subjectHuman immunodeficiency virus infection
dc.subjecthypertension
dc.subjecthypertriglyceridemia
dc.subjectmale
dc.subjectnonhuman
dc.subjectobesity
dc.subjectsitting
dc.subjectsmoking
dc.subjecttriacylglycerol blood level
dc.subjectvirus load
dc.subjectAdult
dc.subjectAntilipemic Agents
dc.subjectAntiretroviral Therapy, Highly Active
dc.subjectCD4-CD8 Ratio
dc.subjectFemale
dc.subjectHIV Infections
dc.subjectHumans
dc.subjectMale
dc.subjectTreatment Outcome
dc.subjectViral Load
dc.titleBezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapyen
dc.typeArtigo
dcterms.licensehttp://www.scielo.br/revistas/bjid/paboutj.htm
unesp.author.lattes1365320427418204[4]
unesp.author.orcid0000-0001-5771-8943[4]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
2-s2.0-33749079204.pdf
Tamanho:
200.41 KB
Formato:
Adobe Portable Document Format
Baixar

Coleções

Artigos - Doenças Tropicais e Diagnósticos por Imagem - FMB